Many neuromuscular conditions are characterized by an exaggerated exercise-induced fatigue response that is disproportionate to activity level. This fatigue is not necessarily correlated with greater central or peripheral fatigue in patients 1 , and some patients experience severe fatigue without any demonstrable somatic disease 2 . Except in myopathies that are due to specific metabolic defects, the mechanism underlying this type of fatigue remains unknown 2 . With no treatment available, this form of inactivity is a major determinant of disability 3 . Here we show, using mouse models, that this exaggerated fatigue response is distinct from a loss in specific force production by muscle, and that sarcolemmalocalized signalling by neuronal nitric oxide synthase (nNOS) in skeletal muscle is required to maintain activity after mild exercise. We show that nNOS-null mice do not have muscle pathology and have no loss of muscle-specific force after exercise but do display this exaggerated fatigue response to mild exercise. In mouse models of nNOS mislocalization from the sarcolemma, prolonged inactivity was only relieved by pharmacologically enhancing the cGMP signal that results from muscle nNOS activation during the nitric oxide signalling response to mild exercise. Our findings suggest that the mechanism underlying the exaggerated fatigue response to mild exercise is a lack of contraction-induced signalling from sarcolemma-localized nNOS, which decreases cGMP-mediated vasomodulation in the vessels that supply active muscle after mild exercise. Sarcolemmal nNOS staining was decreased in patient biopsies from a large number of distinct myopathies, suggesting a common mechanism of fatigue. Our results suggest that patients with an exaggerated fatigue response to mild exercise would show clinical improvement in response to treatment strategies aimed at improving exercise-induced signalling.
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To understand the molecular basis of the exercise-induced fatigue response, we studied genetically defined mouse models. We designed an integrative in vivo assay to test conscious mice, subjecting the mice to brief low-speed treadmill exercise followed by testing in an openfield activity chamber (see Methods). We first assessed two dystrophic mouse lines, mdx (model for Duchenne muscular dystrophy) 4 and Sgca-null (model for limb-girdle muscular dystrophy type 2D that is deficient for the gene encoding a-sarcoglycan (Sgca)) 5 . In the absence of previous exercise, activity in these mice was indistinguishable from that of wild-type mice ( Fig. 1a, b , and Supplementary Videos 1a-d). After a single trial of mild exercise, significant differences were observed ( Fig. 1a, b , and Supplementary Videos 2a-d): the mdx and Sgca-null mice showed a significant decrease in vertical activity.
The decrease in vertical activity among mdx and Sgca-null mice did not correlate with differences in extensor digitorum longus (EDL)specific force measurements relative to those taken in C57BL/6 mice before exercise ( Fig. 1c ). Moreover, Sgca-null mice do not develop brain, heart or vascular pathology 6 , and they have muscle-force values similar to those of control mice 7 . Therefore, neither cardiac deficiency nor an inability to produce force was the cause of the postexercise inactivity in the Sgca-null mice. Because inflammation is a feature of dystrophinopathy 4 , chronic fatigue is associated with muscle pain, and chronic pain is associated with fatigue 8 , we treated mdx mice with either deflazacort or ibuprofen. However, neither treatment resulted in improved post-exercise activity ( Fig. 1d ), suggesting that the inactivity occurring immediately after mild exercise in mdx mice was not due to inflammation or pain. Overall, the results of our exercise-activity assay implied that the exaggerated fatigue response in these mice was not attributable to cardiac deficiency, inflammation, pain or lack of muscle force.
To test whether the exercise-induced inactivity in the mdx and Sgca-null mice was due to the genetically determined structural defect in muscle, we assayed two mouse models in which the muscle pathology related to the specific dystrophin glycoprotein complex (DGC) defect is rescued-microdystrophin/mdx and MCKeSG/ Sgca-null. In microdystrophin/mdx mice (a model for mild Becker muscular dystrophy 9 -the DGC has a mutated but functional dystrophin), microdystrophin is expressed in mdx mouse muscle. In the MCKeSG/Sgca-null mice, e-sarcoglycan is expressed in mouse muscle that is deficient for Sgca ( Supplementary Fig. 1 ). Neither rescue strain showed pathological signs of muscular dystrophy, and the skeletal muscle DGC of both was recovered at the biochemical, structural and functional levels (refs 9, 10 and Supplementary Figs 1 and  2 ).
Despite having a structurally intact skeletal muscle DGC, microdystrophin/mdx mice experience a substantial decrease in activity after mild exercise, like their mdx littermates ( Fig. 1e ). Because patients with Becker muscular dystrophy show profound fatigue after light exertion 11 , and loss of sarcolemma-localized nNOS serves as a diagnostic indicator of some forms of Becker muscular dystrophy 12 , a possible reason for the post-exercise inactivity is a loss of sarcolemma-localized nNOS. To test this possibility we probed for nNOS localization in microdystrophin/mdx skeletal muscle and found that the DGC generated in this rescue strain failed to recruit nNOS to the sarcolemma (Fig. 1e , inset). These data are in agreement with recent reports on microdystrophin expression in dystrophindeficient mouse models 13 . Moreover, the data suggest that exercise-induced inactivity in the microdystrophin/mdx mice is not caused directly by a structurally defective muscle DGC, and that loss of sarcolemmal nNOS does not negatively affect muscle contractility. Thus, sarcolemmal nNOS seems to act at the level of post-exercise activity.
In contrast to the microdystrophin/mdx mice, MCKeSG/Sgca-null mice have structurally intact DGC in the brain and the vasculature, but express e-sarcoglycan instead of a-sarcoglycan in the DGC of muscle. Our exercise-activity assay showed that post-exercise activity in the MCKeSG/Sgca-null mice was substantially decreased relative to that in C57BL/6 mice but similar to that in Sgca-null and mdx mice ( Fig. 1b, f ). Because the microdystrophin-containing DGC failed to recruit nNOS, we speculated that the MCKeSG/Sgca-null mice would also fail to localize nNOS to the sarcolemma. Indeed, although total nNOS levels in muscle homogenates from MCKeSG/Sgca-null mice were similar to those in the wild type, nNOS from the rescue model failed to purify together with the e-sarcoglycan-containing DGC in the membrane preparation ( Fig. 1f , inset). Taken together, these results are compatible with the notion that the exaggerated fatigue response is not directly related to a structurally defective muscle DGC or to muscle weakness, but rather to a failure in the sarcolemmal localization of nNOS.
Because sarcolemma-localized nNOS is crucial for maintaining vasomodulation to contracting muscles 14 , we tested whether communication from skeletal muscle to the local blood supply is deficient after mild exercise by perfusing MCKeSG/Sgca-null mouse arteries before or after exercise with Microfil and examined the skeletal muscle vasculature (Fig. 1g ). We identified vascular narrowings of various lengths along the arteries that feed the skeletal muscles in the post-exercise samples only, and also noted the lack of perfusion of capillaries. The mdx and microdystrophin/mdx mice similarly showed skeletal muscle vascular narrowings only after exercise and also a lack of perfusion of capillaries ( Supplementary Fig. 3c and data not shown). This phenotype is consistent with inefficient contraction-induced muscle nNOS signalling to local blood vessels. Overall, these data imply that loss of sarcolemma-localized nNOS causes deficient exercise-induced vasomodulation in skeletal muscle, and that these lead to prolonged inactivity after mild exercise.
To directly examine the contribution of NO generated by endothelial NOS (eNOS) or nNOS to the exaggerated fatigue response, we tested both nNOS-null and eNOS-null mice in our exercise-activity assay. Mice deficient for nNOS express normal levels of the DGC components at the sarcolemma and have histologically normal muscle [15] [16] [17] . Reports suggest that both mouse strains have defective vasoregulation 18, 19 ; however, mdx and nNOS-null mice have a normal a-adrenergic vasoconstrictive response to exercise 20 . Vertical preexercise activities were similar in eNOS-null, nNOS-null and C57BL/6 mice, suggesting that the loss of either NOS does not affect mouse activity ( Fig. 2a ). After exercise, however, nNOS-null vertical activity decreased significantly ( Fig. 2a ). Serum creatine kinase levels before and after exercise for each of the NOS-null mice were similar to those in C57BL/6 mice and low compared with mdx mice (Fig. 2b) , and there were no signs of muscle pathology in sections from nNOSnull quadriceps muscle ( Supplementary Fig. 4b ), suggesting that muscle damage and necrosis were not the causes of the post-exercise inactivity. We then tested whether post-exercise muscle contractility affected the ability of C57BL/6 and nNOS-null skeletal muscle to produce force after mild exercise. We found that the specific force of EDL muscles after exercise was not significantly affected in nNOSnull muscle in comparison with C57BL/6 muscle ( Supplementary  Fig. 4c ). Because lack of muscle contractility was not causing the inactivity in the nNOS-null mice after exercise, we checked whether NOS-null mice had post-exercise skeletal muscle vascular narrowings and lack of capillary perfusion similar to those in the dystrophic and rescue mice. Microfil perfusion of arteries from NOS-null mice before and after exercise revealed the lack of capillary perfusion and also the presence of vascular narrowings only in post-exercise nNOS-null skeletal muscle (Fig. 2c ). We also found that treating wild-type mice with either the nNOS-specific inhibitor 3-bromo-7nitroindazole or the vasoconstrictor sarafotoxin 6c caused post-exercise inactivity (Fig. 2d) . These findings suggest that a deficiency of sarcolemma-localized nNOS causes exercise-induced narrowing of the vasculature that feeds active muscles after exercise, thereby promoting prolonged inactivity after mild exercise.
To test whether the vascular effect on post-exercise activity was from NO or was downstream of the NO signal, we bypassed sarcolemmal nNOS signalling for decreasing vasoconstriction by treating mdx mice with a panel of pharmacological agents that promote vasodilation; we found that the exaggerated fatigue response was alleviated only by treatment with a phosphodiesterase (PDE) 5A inhibitor ( Supplementary Fig. 6 ), suggesting that the fatigue that we saw depended on cGMP, which acts downstream of NO production. PDE activity in mdx mice is 2-6-fold higher than in C57BL/10 mice 21 , which is consistent with the elevated PDE activity in human muscular disorders 18, 21, 22 . We treated nNOS-null, MCKeSG/Sgca-null and mdx mice with PDE5A inhibitors and tested them in our exercise-activity assay; we found that the treated MCKeSG/Sgca-null and mdx mice showed an increase in post-exercise activity ( Fig. 2e and Supplementary Fig. 7a-d) . Because inhibition of PDE5A had no effect on activity before exercise, our results suggest that PDE5A inhibition is alleviating the exaggerated fatigue response by enhancing the cGMP signal produced by contraction-induced nNOS stimulation. Although downstream effectors of cGMP are numerous and divergent 23 , the half-life of cGMP can be affected by the activity of PDE5A. Our data indicate that the elevated PDE activity in extracts from mdx mice could be PDE5A activity, and that PDE activity could also be elevated in the rescue mouse models we tested.
Our data suggest that the local resistance of arterioles that perfuse sarcolemmal nNOS-deficient muscles increases during exercise and that the lack of activity after mild exercise will lead to muscle oedema. We examined blood flow before and after exercise with laser Doppler imaging and found that blood flow in mdx mice failed to increase as it did in C57BL/6 mice ( Fig. 3a and Supplementary Fig. 7a ), but treatment of mdx mice with a PDE5A inhibitor alleviated this defect (Fig. 3b ) and increased muscle capillary perfusion (Fig. 3c) . Given that insufficient relief of local vasoconstriction in active muscles can lead to muscle oedema 24 , and that boys with Duchenne muscular dystrophy show muscle oedema 25 , we looked for changes in water compartmentalization and dynamics in the hindleg muscles of nNOS-null, C57BL/10 and mdx mice before and after exercise by using spin-spin relaxation time (T 2 )-magnetic resonance imaging. The nNOS-null mice did not have muscle damage or loss of contractility after exercise ( Fig. 2b and Supplementary Fig. 4b, c) , nor did they have muscle oedema ( Supplementary Fig. 8a ), suggesting that their lack of muscle damage prevents water accumulation in the tissue. Similarly, C57BL/10 mice showed little to no oedema in hindleg muscles after exercise (0.70 6 0.50% (mean 6 s.e.m.)) ( Fig. 3f Supplementary Fig. 8b ). However, hindleg muscles of mdx mice consistently showed significant changes in tissue hydration after exercise (25.0 6 2.45% (mean 6 s.e.m.)) ( Fig. 3d, f ) that were indicative of exercise-induced muscle oedema. The water accumulation observed in the mdx muscles is probably due to a combination of the increased local resistance in the arterioles that feed the active leg muscles and of muscle fibre fragility and damage. We also consistently found that treatment with PDE5A inhibitor significantly decreased exercise-induced muscle oedema in mdx mice (3.99 6 0.82% (mean 6 s.e.m.); Fig. 3e, f) . Overall, our data imply that treatment with PDE5A inhibitor can relieve the post-exercise inactivity by normalizing PDE activity, thereby allowing the available NO derived from muscle nNOS to signal for cGMP-dependent vasodilation in active muscle; treatment with PDE5A inhibitor decreases muscle damage in mdx mice by improving modulation of vascular activity in active muscle, thus preventing muscle oedema from exacerbating the muscle damage that occurs during the contraction of dystrophic muscle. Because more than 60% of all patients with neuromuscular disease suffer from severe fatigue 2 , we tested for nNOS localization to the sarcolemma in biopsies of patients representing different myopathic disorders ( Fig. 4, Supplementary Fig. 9 and Supplementary Table 1 ). In most myopathic biopsies assessed, sarcolemma-localized nNOS was either reduced or not detected, implying that many myopathic disorders may share a mechanism that results in severe exerciseinduced fatigue. Although increased fatigability inevitably occurs in patients with muscle weakness 1 , our mouse data imply that the exercise-induced inactivity is distinct from muscle weakness and that loss of sarcolemma-localized nNOS leads to an exaggerated fatigue response to mild exercise.
Our mouse data show that decreased or mislocalized skeletal muscle nNOS exacerbates the fatigue experienced after mild exercise because the normal contraction-induced cGMP-dependent attenuation of local vasoconstriction fails to occur, and that this failure causes vascular narrowing in muscles after exercise. In addition, our data from mdx mice suggest that, as a result of nNOS mislocalization and increased PDE activity 10, 18, 21 , signalling for increased vasodilation to active muscle is deficient, causing muscle oedema. This, in turn, contributes to increased muscle damage as well as profound postexercise debility. Although the exact mechanism that leads to the inactivity after mild exercise has not been reduced to a single beginning and end pathway, our data suggest that contraction-induced cGMP-dependent attenuation of local vasoconstriction is pivotal in this mechanism. These findings could lead to a better understanding of muscle fatigue under other physiological conditions in which muscle nNOS expression, localization or activity is affected.
METHODS SUMMARY
Mouse models. Animal care and procedures were approved and performed in accordance with the standards set forth by the National Institutes of Health and the University of Iowa Animal Care and Use Committee. Treadmill exercise and activity monitoring. Animals were mildly exercised with an adjustable variable-speed belt treadmill from AccuPacer. Activity based on ambulatory behaviour was assessed in an open-field test.
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